Although risks to the patient do exist in the conduct of this study, 
the standard escalating dose nature of this study is designed te minimize the. 
risks to any individual patient. All patients treated in this protocol have 
limited life expectancies due to their advanced cancer and these risks are 
thought to be justified considering the possibility for therapeutic benefit. 
Recombinant DNA Research, Volume 14 
[283] 
